AURA
Aura Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
Consensus Rating "Strong Buy"
Bearish Engulfing
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AURA
Aura Biosciences, Inc.
A biotechnology company that develops novel targeted therapies for cancer
Biological Technology
Invalid Date
10/29/2021
NASDAQ Stock Exchange
106
12-31
Common stock
80 Guest Street, Boston, MA 02135
--
Aura Biosciences, Inc., was incorporated in January 2009 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company that leverages its novel targeted oncology platform to develop a potential new standard of care for multiple cancer indications, initially focusing on ophthalmology and urological oncology. The company's proprietary platform is capable of targeting a wide range of solid tumors using virus-like particles, or VLPs, which can bind to drugs or load nucleic acids to create virus-like drug conjugates, or VDCs. AU-011 is the company's first VDC drug candidate and is being developed for first-line treatment of primary choroidal melanoma, a rare disease for which there is no drug approval.
Company Financials
EPS
AURA has released its 2025 Q1 earnings. EPS was reported at -0.55, versus the expected -0.48, missing expectations. The chart below visualizes how AURA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
